Globus Medical Q1 sales fall 1.4% to $598.1 million; full-year EPS guidance cut
Globus Medical reported first-quarter 2025 net sales of $598.1 million, down 1.4% from a year earlier, while GAAP net income rose to $75.5 million from a loss of $7.1 million. The company cut its full-year 2025 non-GAAP diluted EPS guidance to $3.00 to $3.30 from $3.10 to $3.40, but reaffirmed its full-year revenue guidance of $2.80 to $2.90 billion. Shareholders get a mixed picture: profit improved, but sales declined and the earnings outlook was lowered.
Key points
- Net sales were $598.1 million, down 1.4% (down 0.8% on a constant currency basis); U.S. sales rose 0.2% while international sales fell 7.7%.
- GAAP diluted EPS was $0.54, compared with a loss of $0.05 a year earlier; non-GAAP diluted EPS was $0.68, up from $0.63.
- Full-year 2025 non-GAAP diluted EPS guidance was lowered to $3.00 to $3.30 from $3.10 to $3.40; revenue guidance of $2.80 to $2.90 billion was reaffirmed.
- The company paid off the remaining $450 million of debt assumed from the NuVasive merger and reported free cash flow of $141.2 million.
The filing
Written by AI on Nov 8, 2026, 12:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 08, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.